Testosterone is under clinical development by M et P Pharma and currently in Phase III for Male Hypogonadism. According to GlobalData, Phase III drugs for Male Hypogonadism have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Testosterone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Testosterone overview
Testosterone (Nasobol, Natesto and vogelxo) is a steroid hormone from the androgen group. It is formulated as gel for nasal administration. It is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired), Hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary- hypothalamic injury from tumors, trauma, or radiation. Natesto also indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).
It is under development for the treatment of male hypogonadism.
M et P Pharma overview
M et P Pharma (M et P) is a pharmaceutical and healthcare company. It provides a platform for drug delivery through the intranasal route. The company develops products such as testosterone, developed for patients with multiple sclerosis; dopamine, used for attention deficit hyperactivity disorder; pregnenolone, developed for mild cognitive impairment; and progesterone for insomnia and concussion indications. M et P has a mono-dose container which allows the required amount of oil-based gel into the nostril. The company also provides pre-clinical and clinical studies on male testosterone deficiency, brain treatment malfunctions, PMS and depression, memory-enhancing effects and testosterone formulation. M et P is headquartered in Emmetten, Nidwalden, Switzerland.
For a complete picture of Testosterone’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
